Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT04800588
Recruiting Not applicable

Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

NCT04800588 · tracked via the Priya Life Science USA tracker
Sponsor
Neurobehavioral Systems, Inc
Phase
Not applicable
Started
2021-05-05
Last updated
2025-05-22

Condition(s) studied

Alzheimer DiseaseCognitive DeclineAging

Investigational drug(s) / intervention(s)

California Cognitive Assessment Battery

California Cognitive Assessment Battery: The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.

Study summary

The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests. These tests are designed to permit the early detection of individuals at risk of age-related cognitive decline.

Eligibility

Sex
ALL
Min age
18 Years
Max age
89 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Must be able to use computer mouse and touch screen * Must speak English as a primary language * Must speak Spanish as a primary language (for Latino participants completing our Spanish translation) Exclusion Criteria: * History of psychiatric disorder * History of stroke or transient ischemic attack * History of substance abuse * History of medical or sensory disorders that are incompatible with effective testing * History of traumatic brain injury with hospitalization and extended loss of consciousness * History of epilepsy * History of depression or anxiety

Primary outcome measure(s)

  • Longitudinal normative data collection from healthy participants — Longitudinal testing at six-month intervals
    Multiple behavioral outcome measures will be obtained from each cognitive test including measures of response time (in milliseconds) and accuracy (in percent correct). Recordings of subject's verbal responses will also be analyzed phonologically and automatically transcribed to permit the lexical, syntactic, and semantic analysis of speech output. Questionnaire data will be used to identify factors that may influence performance on the cognitive tests. The primary outcome measures are the scores obtained during enrollment testing that predict a decline in longitudinal performance.

Trial sites (1)

FacilityCityRegionStatus
Neurobehavioral Systems, Inc. Berkeley California Recruiting

Other trials for the same condition

Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems Recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Recruiting
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Active, not recruiting
Open-Label Extension Protocol to SNK01-AD01 Study Recruiting
Clinical Trial on Agitation in Alzheimer's Dementia Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04800588 on ClinicalTrials.gov ↗ ← All trials in the USA